Market Place
Sourcing Support
Zevra Therapeutics Grants Inducement to New CFO Under Nasdaq
20 Mar 2026 //
GLOBENEWSWIRE
Zevra Pharma Sells SDX Portfolio To Commave Pharma For $50M
16 Mar 2026 //
GLOBENEWSWIRE
Zevra Therapeutics Unveils Positive Real-World Miplyffa Data
04 Feb 2026 //
GLOBENEWSWIRE
Zevra Therapeutics To Present MIPLYFFA Analyses
26 Jan 2026 //
GLOBENEWSWIRE
Zevra Expands MIPLYFFA Access For Niemann-Pick Disease
29 Dec 2025 //
GLOBENEWSWIRE
Zevra Therapeutics Names Secor to Board; Dixon Retires
02 Dec 2025 //
GLOBENEWSWIRE
Zevra Therapeutics Announces CFO Transition
20 Nov 2025 //
GLOBENEWSWIRE
Zevra Therapeutics to Present Miplyffa and Olpruva Data
18 Sep 2025 //
GLOBENEWSWIRE
Zevra Reports Data on Miplyffa in Niemann-Pick Disease C
04 Sep 2025 //
GLOBENEWSWIRE
Zevra Files Arimoclomol Review for Niemann-Pick Type C
28 Jul 2025 //
GLOBENEWSWIRE
Zevra Therapeutics Presents Miplyffa® and Olpruva® at SERGG
18 Jul 2025 //
GLOBENEWSWIRE
Zevra` Long-Term Efficacy of MIPLYFFA for NPC Treatment Published
16 Jul 2025 //
GLOBENEWSWIRE
Zevra’s MIPLYFFA® Highlighted at Niemann-Pick Conference
11 Jul 2025 //
GLOBENEWSWIRE
Zevra Therapeutics to Join Citizens Life Science Conference
01 May 2025 //
GLOBENEWSWIRE
Zevra Files Proxy Statement and Mails Letter to Stockholders
21 Apr 2025 //
GLOBENEWSWIRE
Zevra Closes Sale of Rare Pediatric Disease Voucher for $150M
07 Apr 2025 //
GLOBENEWSWIRE
Zevra Therapeutics to Present at the 21st Annual WORLDSymposium
30 Jan 2025 //
GLOBENEWSWIRE
Zevra Therapeutics to Participate at Upcoming Investor Conferences
29 Jan 2025 //
GLOBENEWSWIRE
Zevra Therapeutics to Participate at Upcoming Investor Conferences
26 Nov 2024 //
GLOBENEWSWIRE
Zevra Therapeutic Announces US Commercial Availability of Miplyffa
21 Nov 2024 //
GLOBENEWSWIRE
Zevra to Present Data on Niemann-Pick Disease Type C at CNS
11 Nov 2024 //
GLOBENEWSWIRE
Zevra Therapeutics to Attend Guggenheim Healthcare Conference
06 Nov 2024 //
GLOBENEWSWIRE
Zevra, nonprofit team up to drive diagnosis of rare diseases
10 Oct 2024 //
FIERCE PHARMA
Zevra Joins Rare Disease Panel At 2024 Maxim Healthcare Summit
10 Oct 2024 //
GLOBENEWSWIRE
IntraBio hits the ground running with new rare disease launch
30 Sep 2024 //
FIERCE PHARMA
Zevra Therapeutics to Present KP1077 Data at Sleep Europe 2024
24 Sep 2024 //
GLOBENEWSWIRE
FDA Approves First Treatment for Niemann-Pick Disease, Type C
23 Sep 2024 //
PRNEWSWIRE
Zevra Prices Rare Disorder Drug At Up To $106,000 Per Month
23 Sep 2024 //
REUTERS
Zevra Presents New Data On Arimoclomol And OLPRUVA At SSIEM Symposium
06 Sep 2024 //
GLOBENEWSWIRE
Zevra Therapeutics Announces Proposed Public Offering of Common Stock
08 Aug 2024 //
GLOBENEWSWIRE
Clinical intuition` led FDA advisors to back Zevra`s rare disease med
05 Aug 2024 //
FIERCE BIOTECH
FDA Questions Evidence For Zevra`s Rare Disease Therapy Pre-Adcomm
02 Aug 2024 //
BIOSPACE
FDA Panel Votes Favorably On Arimoclomol For Niemann-Pick Disease Type C
02 Aug 2024 //
GLOBENEWSWIRE
Zevra Acquires Acer for $91M
31 Aug 2023 //
CONTRACT PHARMA
Zevra Reiterates Commitment to Rare Disease Community as Council Member of NORD
28 Feb 2023 //
GLOBENEWSWIRE
Zevra Therapeutics, a Rare Disease Therapeutics Company, Files Preliminary Proxy
27 Feb 2023 //
GLOBENEWSWIRE
